GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
24. Mai 2023 08:00 ET
|
GeoVax, Inc.
New and Unpublished Data from Phase 2 Open-Label Safety Study ofGEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
15. Mai 2023 09:00 ET
|
GeoVax, Inc.
Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
09. Mai 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
04. Mai 2023 16:00 ET
|
GeoVax, Inc.
Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30...
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
26. April 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious...
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
25. April 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and...
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
17. April 2023 09:00 ET
|
GeoVax, Inc.
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
06. April 2023 10:00 ET
|
GeoVax, Inc.
Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax...
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
05. April 2023 13:30 ET
|
GeoVax, Inc.
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
30. März 2023 11:00 ET
|
GeoVax, Inc.
New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...